Welcome to our dedicated page for Algernon Health news (Ticker: AGNPF), a resource for investors and traders seeking the latest updates and insights on Algernon Health stock.
Algernon Pharmaceuticals Inc (AGNPF) generates news primarily around clinical trial developments, regulatory milestones, and corporate transactions typical of clinical-stage pharmaceutical companies. As a drug developer focused on neurological conditions, the company's news flow centers on pipeline progress, research partnerships, and capital market activities.
Pharmaceutical development news from Algernon typically includes updates on clinical trial enrollment, study results, and regulatory interactions with health authorities. The company's drug repurposing approach means announcements may involve new therapeutic applications for existing compounds, patent allowances, and preclinical research findings. Investors tracking AGNPF monitor these developments to assess pipeline advancement and potential value creation.
Corporate news encompasses equity financings, non-dilutive funding announcements, strategic acquisitions, and organizational changes. The company has expanded through acquisitions and maintains active investor relations. Management presentations, conference participation, and partnership announcements provide context on corporate strategy and development priorities.
The Algernon NeuroScience division generates specific news related to brain health research and neurological drug candidates. Clinical trial updates, research collaborations with academic institutions, and CRO partnerships are common news themes. Patent filings and allowances indicate intellectual property development supporting the company's pipeline.
Following Algernon Pharmaceuticals news helps investors track the binary events that characterize clinical-stage pharmaceutical companies. Trial readouts, regulatory decisions, and funding announcements can significantly impact share price and company trajectory. Bookmark this page to monitor developments as the company advances its drug development programs.
Algernon Pharmaceuticals has successfully completed its non-brokered private placement, issuing 11,260,040 units at CDN $0.25, raising gross proceeds of CDN $2,815,010. Each unit consists of one Class A common share and a warrant. The warrants allow for the purchase of additional shares at CDN $0.40 until March 5, 2023, with terms for accelerated expiry. The company paid CDN $161,400 in commissions and issued 645,600 finder’s warrants. Proceeds will be utilized for general corporate purposes.
Algernon Pharmaceuticals has announced a discussion on their DMT Stroke Clinical Research Program featuring CEO Christopher J. Moreau and DMT Consultant Dr. David Nutt. The BioPub webcast is scheduled for March 3, 2021, at 1:00 PM EST, inviting stakeholders to engage in the conversation about the company's innovative approach to drug repurposing. Algernon focuses on exploring safe, approved drugs for new therapeutic applications, aiming to expedite new human trials and regulatory approvals.
Algernon Pharmaceuticals has announced a non-brokered private placement of 10,800,000 units, raising CAD $2,700,000. Each unit includes a common share priced at $0.25 and a share purchase warrant exercisable at $0.40 for 24 months. The warrants may expire early if the shares trade at or above CAD $0.80 for ten consecutive days. The proceeds will be allocated for general corporate purposes. Algernon focuses on drug repurposing for new disease applications, developing formulations, and seeking regulatory approvals.
Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: AGNPF) has awarded Hammersmith Medicines Research Ltd a contract for its Phase 1 stroke study of AP-188 (DMT). This study aims to assess the safety, tolerability, and pharmacokinetics of DMT dosages in healthy participants. Algernon plans to be the first globally to explore prolonged intravenous DMT infusion for stroke treatment. The study is set to inform future Phase 2 trials in stroke patients and is expected to start following the acquisition of cGMP drug product from Dalton Pharma.
Algernon Pharmaceuticals has appointed Dr. Christopher Bryan as Vice President of Research & Operations and Dr. Ahmad Khalil as Chief Medical Officer. Dr. Bryan, a PhD graduate from the University of Toronto, brings extensive experience in drug synthesis and clinical trial management. Dr. Khalil has over 20 years in biopharma, overseeing multiple clinical trials. The company announced that Dr. Mark Williams will step down as Chief Science Officer to lead a new venture. Algernon focuses on repurposing approved drugs for new applications.
On February 25, 2021, Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) announced that CEO Christopher J. Moreau and Dr. David Nutt will discuss the Company's New DMT Stroke Clinical Research Program at the Psychedelic Capital Virtual Investment Conference. This presentation will take place at 4:45 PM EST and is open for free access to shareholders, investors, and the public. Interested parties can find further information and access a free ticket through the provided link. Algernon is focused on drug repurposing and investigating safe, approved drugs for new medical applications.
Algernon Pharmaceuticals Inc. (CSE: AGN) has awarded a contract to Dalton Pharma Services for the manufacturing of the active pharmaceutical ingredient and finished product of AP-188 (DMT). This collaboration aims to facilitate the synthesis of DMT as Algernon prepares to file for a pre-IND meeting with the U.S. FDA and advance its Phase 1 and 2 clinical studies. The company is focused on leveraging positive pre-clinical data indicating DMT's potential in stroke treatment, with ongoing investigations into its effects on neuroplasticity.
On February 17, 2021, Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: AGNPF) updated on its Phase 2b/3 study of Ifenprodil for COVID-19. A fire at a Romanian hospital site delayed the site audit, but the company has completed the source data audit for all patients. The database will be locked for analysis on March 5, and results will be shared soon after. Notably, many patients received imaging scans, aiding the exploration of Ifenprodil's potential in reducing post-COVID lung scarring, although the data will be reviewed separately to avoid further delays.
Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: AGNPF) announced plans to review its Phase 2b/3 study protocol for Ifenprodil in treating COVID-19, considering adding lung scarring as an endpoint based on new data from a significant patient population. Although lung scarring was not previously recognized as a major issue, recent studies indicate that 60% of post-COVID-19 patients exhibit lung damage. CEO Christopher J. Moreau emphasized that confirming Ifenprodil's effectiveness in this area could represent a significant advancement in patient care.
Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) announced a partnership with Charles River Laboratories to conduct preclinical studies on AP-188 (DMT) for its stroke research program. The study aims to explore DMT's neurogenic potential. The company intends to initiate human trials in 2021, focusing on sub-hallucinogenic doses to avoid adverse psychedelic effects in stroke patients. Previous studies indicated DMT's efficacy in reducing brain injury and promoting recovery. Algernon aims to be the first to investigate DMT for stroke treatment in humans.
FAQ
What is the current stock price of Algernon Health (AGNPF)?
What is the market cap of Algernon Health (AGNPF)?
